-
In big man US football league, guys score a different kind of goal
-
Trump heads for Xi summit overshadowed by Iran war
-
New York governor orders US immigration agents to unmask
-
Arsenal sense Premier League glory as Spurs eye safety
-
Pitch for World Cup final installed at US stadium
-
IS-linked Australian women charged with keeping slave in Syria
-
Venezuela admits death of political prisoner in custody nearly one year later
-
Lee leads by one at LPGA Mizuho Americas Open
-
Hot-putting McCarty seizes PGA lead at Quail Hollow
-
CPJ demands progress on US probe of journalist Abu Akleh killing, four years on
-
'Elitist' World Cup leaves Mexican soccer family on sidelines
-
Palace overcome Shakhtar to reach historic Conference League final
-
Watkins salutes Emery after Villa reach Europa final
-
AI actors not eligible for Golden Globes, say organizers
-
Kuebler brace sends Freiburg past Braga into Europa League final
-
Rayo down Strasbourg in Conference League to set up first European final
-
Villa crush Forest to reach Europa League final against Freiburg
-
Brazil's Lula and Trump hail positive talks after rocky relations
-
Shakira teases new World Cup song
-
Palace beat Shakhtar to reach first European final
-
Rail fare to World Cup final stadium is cut ... to $105
-
Global stocks mostly fall as US rally shows signs of fatigue
-
Sabalenka, champion Paolini open Italian Open accounts
-
Trump gives EU until July 4 to ratify deal or face tariff hike
-
30 passengers left hantavirus ship in Saint Helena: cruise operator
-
Real Madrid to punish Valverde, Tchouameni after training ground clash
-
French parliament votes to ease returns of looted art to ex-colonies
-
Ancelotti set for Brazil contract extension: federation
-
Civilians lynched in Mali witch hunt after jihadist, rebel attacks
-
US targets Cuban military, mine in new sanctions
-
Marsh ton sets up Lucknow win in rain-hit IPL clash
-
Google faces new UK lawsuit over online display ads
-
Yankees outfielder Dominguez collides with wall making catch
-
NY to hire 500 addiction recovery mentors with opioid settlement cash
-
Trump says he would not pay $1,000 to watch US at World Cup
-
Dubois vows to take out 'trash' WBO heavyweight champion Wardley
-
France to ban CBD edibles: sources
-
Twin jihadist-claimed attacks kill more than 30 in Mali
-
US oil blockade on Cuba 'energy starvation': UN experts
-
Zelensky warns against attending Russia's parade as Moscow repeats threats
-
Millwall eye 'fairytale' in Championship play-offs
-
Hantavirus not like Covid: doctor treating patient in Netherlands
-
Covid flashbacks haunt Canary Islands as hantavirus ship nears
-
IOC lifts Olympic ban on Belarus but Russia 'still suspended'
-
IMF warns of 'inevitable' AI-powered threats to global financial system
-
Brighton boss Hurzeler agrees new three-year deal
-
WHO says now five confirmed cruise ship hantavirus cases
-
Spurs boss De Zerbi shrugs off criticism of win over weakened Villa
-
Sinner demands 'respect' from Grand Slams, Djokovic lends support in prize money row
-
Germany warns tax revenues to be hit by Iran war
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
F.Ferraz--PC